GSK Predicts Outsourcing R&D To “Low-Cost” Countries Could Save $200 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Each outsourced clinical trial patient could save GSK up to $15,000, CEO Garnier estimates. The company is exploring a number of ways to control R&D costs, the exec says, citing electronic data capture as another potential option.
You may also be interested in...
Industry Should Outsource R&D To Manage Drug Development Costs, HGS CEO Says
Nearly all aspects of the drug development process can be done in other countries at substantial savings, Human Genome Sciences' Haseltine says. Outsourcing could reduce costs by up to two-thirds and allow greater flexibility, he maintains.
Internal R&D vs. CROs: AstraZeneca, Novartis Tout Advantages Of Staying In-House
Novartis reports savings of $100 mil. by decreasing its use of contract research organizations. AstraZeneca sees improved R&D productivity by relying less on CROs and by conducting clinical trials outside the U.S.
US FDA Oncology Diagnostics Pilot Is ‘Interim Step’ To Fill VALID Void, But ‘Stuck In Neutral’
Without sponsors willing to work with them and in the absence of legislation giving FDA authority over lab-developed tests, the agency has launched internal programs to both gain more oversight – and spur innovation.